ASH 2024 Summary: Myeloma Highlights and Impact on Practice

2024 ASH Annual Meeting Insights Hub

H. Hashmi

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk

Dana-Farber Cancer Institute

P. Richardson

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

2024 ASH Annual Meeting Insights Hub

A. Perrot

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th …

Springer Healthcare IME

S. Usmani

Multiple Myeloma: Hot Topics in 2024

Yale Cancer Center

S. Browning

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

A New Consensus for Classification of High-Risk Myeloma Based on Cyt…

Jill Corre

ASH 2024 Insights: Analyses of MRD Negativity Dynamics in the Phase …

2024 ASH Annual Meeting Insights Hub

R. Orlowski

ASH 2024 Insights: Dara vs. Len Maintenance in NDMM - Interim Result…

2024 ASH Annual Meeting Insights Hub

U. Shah

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

Indefinite Treatment of Multiple Myeloma: Strategies for Frail Patie…

Shaji Kumar

Evaluating Infection Risk in CAR T-Cell Therapy and Bispecific Antib…

Meera Mohan